证券代码：600774 股票简称：汉商集团 编号：2024-022 汉商集团股份有限公司 为确保公司监事会工作顺利开展，公司股东武汉市汉阳投资发展集团有限公 司提名李弘先生（简历附后）为公司非职工监事。公司于2024年4月25日召开第 十一届监事会第十次会议，审议通过了《关于变更公司非职工监事的议案》，同 意李弘先生为非职工监事候选人，任期自股东大会审议通过之日起至第十一届监 事会届满之日止。本议案尚需提交公司股东大会审议批准，待股东大会审议通过 后，公司将再次召开监事会选举监事会主席。 特此公告。 汉商集团股份有限公司监事会 2024 年 4 月 26 日 附：李弘先生简历 关于变更公司非职工监事的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 因公司监事曾凡龙先生退休，不再担任公司监事、监事会主席职务。根据《公 司法》和《公司章程》的相关规定，曾凡龙先生的离职将导致本公司监事会低于 法定最低人数3名。为保证公司监事会的正常运作，在股东大会选举产生新任监 事之前，曾凡龙先生将继续履行监事会监事职责。 曾凡龙先生在任职期 ...

证券代码：600774 证券简称：汉商集团 公告编号：2024-030 | | | | 主营业务分行业情况 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 分行业 | 营业收入 | 营业成本 | 毛利率 | 营业收入 | 营业成本 | 毛利率比 | | | | | | （%） | 比上年增 | 比上年增 | 上年增减 | | | | | | | 减（%） | 减（%） | （%） | | | 药品 | 239,199,380.16 | 127,450,232.50 | 46.72 | -3.05 | 15.32 | 减少 8.48 | | | | | | | | | 个百分点 | | | 医疗器 | 17,944,564.30 | 3,079,766.07 | 82.84 | 0.61 | 48.40 | 减 少 | 5.52 | | 械 | | | | | | 个百分点 | | | 商业运 | 53,622,733.07 | 11,698,403.43 | 78.18 | -8.57 | -12.19 | 增加 | 0.9 个 | ...

证券代码：600774 证券简称：汉商集团 编号：2024-026 汉商集团股份有限公司 关于会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●本次会计政策变更是公司根据财政部修订的相关企业会计准则而进行的相应变更， 不会对公司财务状况、经营成果和现金流量产生重大影响。 2024 年 4 月 25 日，汉商集团股份有限公司（以下简称"公司"）第十一届 董事会第十八次会议和第十一届监事会第十次会议，分别审议并一致通过了 《关于会计政策变更的议案》。 一、本次会计政策变更概述 1、会计的政策变更原因 财政部于 2022 年 11 月 30 日发布了《关于印发〈企业会计准则解释第 16 号〉的通知》（财会〔2022〕31 号，以下简称"《解释 16 号》"），规定 "关于单项交易产生的资产和负债相关的递延所得税不适用初始确认豁免的会 计处理"的内容，自 2023 年 1 月 1 日起施行。 2、变更前采用的会计政策 本次变更前，公司执行财政部发布的《企业会计准则——基本准则》和各 项具体会计准则、 ...

汉商集团股份有限公司 二〇二三年度独立董事述职报告 ——独立董事 胡浩 作为汉商集团股份有限公司（"汉商集团"或"公司"）的独立董事，本 人严格按照《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）、《上海证券交易所股票上 市规则》（"《上交所上市规则》"）、《上市公司独立董事管理办法》等法 律法规和规范性文件的规定，以及汉商集团《公司章程》《独立董事工作制 度》等规定，切实履行独立董事忠实勤勉义务，积极为公司经营发展建言献 策，努力维护公司利益及全体股东特别是中小股东的合法权益。现将本人 2023 年度履行职责的具体情况报告如下： 一、独立董事基本情况 胡浩，男，1981 年 9 月出生，中共党员，研究生学历，硕士学位。2004 年 -2008 年任滁州职业技术学院财务管理系讲师，2008 年至今历任宇业集团有限 公司董事长秘书，项目公司总经理。现任宇业集团有限公司常务副总裁，江苏 光宇兆能新能源科技有限公司董事长。 本人符合相关法律法规关于独立董事独立性的要求，不存在任何影响独立 性的情况。 二、2023 年度履职情况 2023 年，本人积极参加公司召 ...

Financial Performance - The company's operating revenue for 2023 was CNY 1,389,601,286.62, a slight increase of 0.19% compared to CNY 1,386,976,174.51 in 2022[20] - The net profit attributable to shareholders for 2023 decreased by 32.24% to CNY 61,206,384.07 from CNY 90,333,223.18 in the previous year[20] - The net profit after deducting non-recurring gains and losses was CNY 37,693,074.00, down 15.67% from CNY 44,699,593.43 in 2022[20] - The cash flow from operating activities for 2023 was CNY 247,182,519.46, an increase of 2.00% compared to CNY 242,346,281.77 in 2022[20] - The total assets at the end of 2023 were CNY 3,694,821,482.47, reflecting a 5.00% increase from CNY 3,518,929,925.59 at the end of 2022[20] - The net assets attributable to shareholders increased by 0.50% to CNY 1,675,094,041.05 from CNY 1,666,741,386.04 in 2022[20] - Basic earnings per share for 2023 were CNY 0.2075, a decrease of 32.24% from CNY 0.3062 in 2022[21] - The weighted average return on equity for 2023 was 3.67%, down from 5.48% in 2022, a decrease of 1.81 percentage points[21] Shareholder Returns - The company plans to repurchase shares amounting to CNY 35,491,741.23, which is considered as cash dividends, accounting for 57.99% of the net profit attributable to shareholders for 2023[5] - In 2023, the company did not propose any cash dividend distribution, with a total of ¥35,491,741.23 used for share repurchase, representing 57.99% of the net profit attributable to ordinary shareholders[167] Industry Trends - The pharmaceutical manufacturing industry faced challenges, with a reported revenue decline of 4% and profit drop of 16.2% in 2023, primarily due to decreased demand for COVID-19 vaccines and rising costs of traditional Chinese medicine[31] - The pharmaceutical manufacturing industry in China saw a decline in key metrics: the added value of large-scale pharmaceutical industry was approximately CNY 1.3 trillion, down 5.2% year-on-year; revenue was CNY 2,955.25 billion, down 4%; and profit was CNY 412.72 billion, down 16.2%[80] - The pharmaceutical manufacturing industry experienced a "W" shaped quarterly trend in 2023, with a decline in Q1, a narrowing drop in Q2, a further dip in Q3, and a recovery in Q4[80] - The new medical insurance drug list for 2023 added 126 drugs and removed 1 drug, with a negotiation success rate of 84.6% and an average price reduction of 61.7%[81] - By the end of 2023, there were 9,345 large-scale pharmaceutical manufacturing enterprises in China, indicating a low market concentration with many small and medium-sized enterprises[86] - The pharmaceutical manufacturing industry is focusing on high-quality development, emphasizing technological innovation, internationalization, and advanced manufacturing[86] Product Development and Innovation - The company is actively pursuing new product development in aesthetic medicine, achieving domestic leadership in technology for injectable microspheres[28] - The company has 97 pharmaceutical products on the market, focusing on areas such as the digestive system, respiratory system, and anti-infection[36] - The company’s core product, Tongqiao Biyan Granules, has a market share exceeding 85% in the hospital channel and 92.88% in the retail market, ranking first in both categories[38] - The company achieved a total revenue of 138,960.13 million yuan in the reporting period, representing a year-on-year increase of 0.19%[55] - The company completed the technological achievement evaluation of the polylactic acid microsphere project, achieving a leading level in domestic absorbable injection microsphere technology[42] - The company has established a new process development team focused on multiple sports medicine product developments[42] - The company has expanded its core technology reserves, completing one patent application during the reporting period[42] Market Expansion and Sales Strategy - The company is expanding its distribution model, transitioning from direct sales to a dealer model in the medical device sector[58] - The company has a sales team of over 400 members, covering more than 10,000 hospitals and nearly 300,000 retail pharmacy stores nationwide[51] - The company’s OTC sales team covers all provinces in China, enhancing product promotion and distributor network management[108] - The company’s sales strategy includes participation in centralized drug procurement and tender procurement, ensuring effective distribution to end hospitals[108] Research and Development - The total R&D investment for the year 2023 amounted to RMB 45.26 million, with RMB 40.13 million classified as expense-based R&D and RMB 5.13 million as capitalized R&D, resulting in a capitalized R&D ratio of 9.27%[104] - The company reported a R&D investment of RMB 19.91 million for the DDCI-01 project, accounting for 1.43% of operating revenue, with a year-on-year increase of 16.59%[106] - The average R&D investment among comparable companies in the industry was RMB 22.74 million, with the company's R&D investment representing 3.47% of operating revenue and 2.88% of net assets[106] - The company’s R&D investment in the project for Esomeprazole Sodium was RMB 270.66 million, reflecting a significant increase of 72.32% compared to the previous year[106] - The company’s R&D investment in Acetaminophen Tablets was RMB 306.08 million, with no applicable year-on-year change reported[106] Environmental and Social Responsibility - The company invested ¥600,000 in environmental protection during the reporting period[174] - The company has established a mechanism for environmental protection and received a national pollutant discharge permit for its subsidiary, which is a key pollutant discharge unit[175] - The company achieved wastewater treatment compliance with a total nitrogen concentration of 3.59 mg/L, well below the limit of 20 mg/L[176] - The company reported a total phosphorus concentration of 0.06 mg/L, significantly lower than the 0.5 mg/L requirement[176] - The company has implemented a comprehensive environmental monitoring plan, ensuring all pollutant emissions are within acceptable ranges throughout 2023[180] - The company invested a total of 35.3 million yuan in social responsibility initiatives, including donations to education and healthcare[185] - The company has been recognized as an "Environmental Credit Good Enterprise" in 2023, reflecting its commitment to environmental management[181] Management and Governance - The company reported a total of 44,330,715 shares outstanding[150] - The term for the current supervisory board members is set to end in March 2025[147] - The company has appointed a new vice president, Wang Guannan, nominated by the president[150] - The company’s governance structure includes a compensation committee that aligns remuneration with performance metrics[149] - The company’s board of directors has established specialized committees, including an audit committee and a strategic committee, to oversee various functions[156] - The company approved a financing proposal to apply for bank loans during the 11th board meeting in January 2023[152] Strategic Acquisitions and Partnerships - The company acquired a 25% stake in Huake Reproductive Hospital for 57.5 million RMB and later acquired 81.34% of the hospital for 75.34 million RMB, achieving absolute control over the hospital[115] - The company plans to acquire 100% equity of Zheng'an Industrial (Wuhan) Co., Ltd. and operational assets of the "Wuhan Living Room Project" through a combination of share issuance and cash payment[192] - The company will coordinate with relevant parties to complete the audit, evaluation, and due diligence for the aforementioned transactions[193] Challenges and Risks - The company acknowledges the high risks associated with R&D innovation, including patent issues and the long development cycles of new drugs and medical devices[132] - The cost of traditional Chinese medicine has increased significantly, with prices of key herbs like Fangfeng, Xinyu, and Kuandonghua rising over 200% since December 2022, impacting the cost of traditional Chinese medicine products in 2023[133] - The company faces intensified competition in the retail market due to policy changes and increased market competition, necessitating a multi-channel growth strategy[131]

证券代码：600774 证券简称：汉商集团 公告编号：2024-029 汉商集团股份有限公司 关于召开 2023 年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2023 年年度股东大会 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票 相结合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2024 年 5 月 16 日 14 点 30 分 召开地点：武汉市汉阳区汉阳大道 134 号公司本部 8 楼 801 会议室 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 5 月 16 日 至 2024 年 5 月 16 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联 ...

证券代码：600774 股票简称：汉商集团 编号：2024-021 汉商集团股份有限公司 第十一届监事会第十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 汉商集团股份有限公司（以下简称"公司"）于2024年4月15日发出关于召 开第十一届监事会第十次会议（以下简称"本次会议"）的通知，本次会议于2024 年4月25日在公司会议室召开，应出席监事3人，实际出席2人，监事曾凡龙先生 因退休未出席本次会议。会议分别审议通过了以下议案： 一、公司2023年度报告及摘要 四、关于变更公司非职工监事的议案 同意2票，反对0票，弃权0票。 监事会对公司2023年年度报告及摘要进行了审核，认为：公司2023年度报告 的内容和格式符合中国证监会和上海证券交易所的有关规定；所披露的信息真实、 完整地反映了公司本年度的经营管理和财务状况等事项；公司2023年度报告的编 制和审议程序符合法律、法规、《公司章程》和《公司内部控制制度》的各项规 定；公司监事会在提出本意见之前，未发现参与年报编制和审议的人员有违反保 密规定的行为。 二、 ...

证券代码：600774 股票简称：汉商集团 编号：2024-019 汉商集团股份有限公司 关于重大资产重组进展公告 本公司及董事会全体成员保证公告内容不存在虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实、准确和完整承担个别及连带责任。 一、本次交易基本情况 汉商集团股份有限公司（以下简称"公司""汉商集团""上市公司"）拟 通过发行股份的方式向卓尔国际商业管理武汉合伙企业（有限合伙）、正安资产 （开曼群岛）实业股份有限公司购买其持有的正安实业（武汉）有限公司 100%股 权，拟通过发行股份及支付现金的方式向卓尔城投资发展有限公司购买其持有的 "武汉客厅项目经营性资产"，同时，向不超过 35 名特定对象发行股份募集配 套资金（以下简称"本次交易"）。本次交易预计构成重大资产重组，构成关联 交易，不构成重组上市。 二、本次交易的历史披露情况 根据上海证券交易所（以下简称"上交所"）相关规定，经公司申请，公司 股票自 2023 年 8 月 18 日开市起停牌，具体内容详见公司于 2023 年 8 月 18 日 在上交所网站（www.sse.com.cn）披露的《汉商集团股份有限公司筹划重大资产 重组停牌公告》 ...

证券代码：600774 股票简称：汉商集团 编号：2024-018 汉商集团股份有限公司 | 序 | 收款单位 | 项目内容 | 获得时间 | 补贴金额 | | 补贴依据 | | --- | --- | --- | --- | --- | --- | --- | | 号 | | | | 收益相关 | 资产相关 | | | 27 | 成都迪康中科 生物医学材料 | 科创贷利息补 贴 | 2024/4/10 | 110,700.00 | | 成都市科学技术局关 于组织申报 2024 年成 都市第一批科技项目 | | | 有限公司 | | | | | | | | | | | | | 的通知 | | 28 | 拉萨迪康医药 | 2023 年企业扶 | 2024/4/19 | 10,893,356.00 | | 拉经开经发【2024】 | | | 科技有限公司 | 持发展金 | | | | 38 号 | | | 合计 | | | 15,902,339.82 | 1,980,000.00 | | 二、补贴的类型及其对公司的影响 关于获得政府补贴的公告 本公司及董事会全体成员保证公告内容不存在虚假记载、误导性陈述或者重大遗 ...

证券代码：600774 证券简称：汉商集团 公告编号：2024-017 汉商集团股份有限公司 2024 年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 13 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 169,545,413 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总 | 58.6646 | | 数的比例（%） | | （截至股权登记日，公司总股本为 295,032,402 股，公司回购专用证券账户内共有 6,024,130 股公司股份，公司享有表决权的股份总数为 289,008,272 股。） (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 二、 议案审议情况 表决情况： | 股东类型 | 同意 | | 反对 | | 弃权 | | | --- | --- | --- | --- | --- ...